Freestone Grove Partners’s KalVista Pharmaceuticals KALV Stock Holding History

Freestone Grove Partners’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-882,906	Closed	-$17.8M	–	1185
2026 Q1	$17.8M	Buy	882,906 +249,887	+39%	+$4.03M	0.13%	224
2025 Q4	$10.2M	Sell	633,019 -71,429	-10%	-$946K	0.07%	286
2025 Q3	$8.58M	Buy	+704,448	New	+$9.73M	0.06%	302

Other funds holding KALV

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Freestone Grove Partners's KALV Position: Q2 2026 in Review

Freestone Grove Partners sold out of KalVista Pharmaceuticals (KALV) in Q2 2026, closing a stake of 882,906 shares — an estimated $17.8M sold.

Freestone Grove Partners first reported a position in KALV in Q3 2025 and held it in 3 quarters. The position peaked at $17.8M in Q1 2026. 1 fund tracked by Wall St. Rank holds KALV as of Q2 2026.

Freestone Grove Partners reported no remaining KalVista Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Freestone Grove Partners sold 882,906 KalVista Pharmaceuticals shares in Q2 2026, an estimated $17.8M.
Freestone Grove Partners first reported a position in KalVista Pharmaceuticals in Q3 2025 and held it in 3 quarters.
Freestone Grove Partners's KalVista Pharmaceuticals position peaked at $17.8M in Q1 2026.
1 fund tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q2 2026.

Based on Freestone Grove Partners's 13F filing for Q2 2026, filed 14 Aug 2026.